Peter Ding, Allorion Therapeutics co-founder and CEO
A fledgling transpacific biotech grabs a launch round to dive into oncology and autoimmune research
Precision-med biotech Allorion Therapeutics is expanding — and now has tens of millions of dollars more to work with.
The Natick, MA-based company announced in a statement this morning that it closed a Series A round, bringing in $40 million. Shanghai VC Qiming Venture Partners led the round, which also includes a number of both new and old investors — Octagon Capital, IDG Capital and TF Capital, to name a few.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters